ADMA Biologics Inc vs Global X Copper Miners ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Global X Copper Miners ETF trades at $88.55. The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | COPX | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $95.70 |
52-Week Low | $7.60 | $46.08 |
Enterprise Value | $2.25B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
COPX, the Global X Copper Miners ETF, trades at $88.03, up 2.25% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides exposure to copper mining equities, which are leveraged to copper demand from AI data centers and electrification trends. Recent news highlights institutional accumulation and a buying opportunity after a pullback from 2026 highs.
The outlook is positive due to structural copper demand growth, though mining equities have underperformed copper futures year-to-date. Risks include commodity price volatility and supply bottlenecks. Analyst sentiment is bullish, emphasizing COPX as a pick-and-shovel play on AI infrastructure.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →